Ajmal Muhammad S, Parikh Umang M, Lamba Harveen, Walther Carl
Nephrology, Baylor College of Medicine, Houston, USA.
Surgery, Baylor College of Medicine, Houston, USA.
Cureus. 2020 Apr 18;12(4):e7725. doi: 10.7759/cureus.7725.
Introduction Left ventricular assist devices (LVAD) are used as a bridge to heart transplant or destination therapy for patients with the New York Heart Association (NYHA) class 3 or 4 heart failure. Acute kidney injury (AKI) or need for renal replacement therapy (RRT) post-LVAD implant can lead to poor outcomes. Identifying risk factors of AKI post-LVAD implant can help stratify potential LVAD candidates. Methods This is a retrospective study of all patients who received continuous-flow LVAD at our institution from January 2015 until August 2017. We calculated the incidence of AKI and the need for RRT post-LVAD implant, as well as the rate of renal recovery and survival rates at 30 days and 1-year post-LVAD implant. The presence of chronic kidney disease (CKD) and proteinuria was assessed, and kidney ultrasound results were reviewed on all patients, if available. CKD was present if estimated glomerular filtration rate (eGFR) was <60 mL/min per 1.73m for ≥3 months preceding LVAD implant and/or presence of proteinuria ≥ 20 mg/dL on two or more urine samples prior to LVAD implant and/or an abnormal kidney ultrasound with increased echogenicity, small size <9 cm or scarring. AKI was defined as per the current Kidney Disease Initiative Global Outcomes (KDIGO) guidelines. Results A total of 137 patients received LVAD during this time period. There were 112 males and 25 females with a mean age of 59.2 years. Incidence of AKI and the need for RRT post-LVAD implant were 64% and 19.7%, respectively. Sub-group analysis was performed based on the presence of CKD, advanced CKD stage (Stage 1-2 vs 3-5), proteinuria and abnormal kidney ultrasound. The incidence of AKI post-LVAD implant was significantly higher if baseline CKD was present ( = 0.028), and patient had an advanced CKD stage ( = 0.008). The need for RRT post-LVAD implant was significantly higher if baseline CKD was present (= 0.015), and the patient had an abnormal kidney ultrasound (= 0.04). Thirty-day and one-year mortality rates post-LVAD implants were 4.3% and 21.1%, respectively for the entire cohort. Out of the 27 patients requiring RRT, nine (33.3%) came off RRT before one year. Compared to the eGFR on the day of LVAD implant, eGFR at 30 days post-LVAD implant was higher in 57% and lower in 42% patients. At one year, this eGFR improvement reversed and eGFR was lower in 67% and higher in 32% patients. Conclusion The incidence of AKI and need for RRT post-LVAD implant are very high. The presence of CKD, advanced CKD stage, and an abnormal kidney ultrasound are statistically significant risk factors of AKI post-LVAD implant and/or need for RRT. Identifying these renal risk factors can help stratify the potential LVAD candidates. Only one out of three patients requiring RRT achieved dialysis independence by one-year post-LVAD implant.
引言
左心室辅助装置(LVAD)被用作纽约心脏协会(NYHA)3或4级心力衰竭患者心脏移植的桥梁或终末期治疗手段。LVAD植入术后发生急性肾损伤(AKI)或需要进行肾脏替代治疗(RRT)会导致不良预后。识别LVAD植入术后AKI的危险因素有助于对潜在的LVAD候选者进行分层。
方法
这是一项对2015年1月至2017年8月在我们机构接受连续血流LVAD治疗的所有患者的回顾性研究。我们计算了LVAD植入术后AKI的发生率和RRT的需求,以及LVAD植入术后30天和1年时的肾脏恢复率和生存率。评估慢性肾脏病(CKD)和蛋白尿的存在情况,并在所有患者中回顾肾脏超声检查结果(如有)。如果在LVAD植入前≥3个月估计肾小球滤过率(eGFR)<60 mL/(min·1.73m²)和/或在LVAD植入前两份或更多份尿液样本中蛋白尿≥20 mg/dL和/或肾脏超声异常,表现为回声增强、肾脏尺寸<9 cm或有瘢痕,则存在CKD。AKI根据当前的肾脏疾病改善全球结果(KDIGO)指南进行定义。
结果
在此期间共有137例患者接受了LVAD治疗。其中男性112例,女性25例,平均年龄59.2岁。LVAD植入术后AKI的发生率和RRT的需求分别为64%和19.7%。根据CKD的存在情况、晚期CKD分期(1 - 2期与3 - 5期)、蛋白尿和肾脏超声异常进行亚组分析。如果存在基线CKD(P = 0.028)且患者处于晚期CKD分期(P = 0.008),LVAD植入术后AKI的发生率显著更高。如果存在基线CKD(P = 0.015)且患者肾脏超声异常(P = 0.04),LVAD植入术后RRT的需求显著更高。整个队列中LVAD植入术后30天和1年的死亡率分别为4.3%和21.1%。在27例需要RRT的患者中,9例(33.3%)在1年内停止了RRT。与LVAD植入当天的eGFR相比,LVAD植入术后30天,57%的患者eGFR升高,42%的患者eGFR降低。1年时,这种eGFR的改善情况逆转,67%的患者eGFR降低,32%的患者eGFR升高。
结论
LVAD植入术后AKI的发生率和RRT的需求非常高。CKD的存在、晚期CKD分期以及肾脏超声异常是LVAD植入术后AKI和/或RRT需求的统计学显著危险因素。识别这些肾脏危险因素有助于对潜在的LVAD候选者进行分层。在需要RRT的患者中,只有三分之一的患者在LVAD植入术后1年实现了透析独立。